Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.

Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T; European CF Society (ECFS) Strategic Planning Task Force on ‘Speeding up access to new 4 drugs for CF’, Amaral MD, de Boeck K, Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T.

J Cyst Fibros. 2019 Sep;18(5):677-684. doi: 10.1016/j.jcf.2019.06.011. Epub 2019 Jul 11.

PMID:
31303382
2.

Sleep disorders in patients with primary ciliary dyskinesia, cystic fibrosis with and without pancreatic insufficiency.

Cohen-Cymberknoh M, Atia O, Gileles-Hillel A, Kerem E, Reiter J.

Respir Med. 2019 May;151:96-101. doi: 10.1016/j.rmed.2019.03.022. Epub 2019 Apr 5.

PMID:
31047123
3.

Giant lung cysts following necrotizing pneumonia: Resolution with conservative treatment.

Gross I, Gordon O, Cohen-Cymberknoh M, Reiter J, Tsabari R, Gileles-Hillel A, Erlichman I, Hevroni A, Shoseyov D, Kerem E.

Pediatr Pulmonol. 2019 Jun;54(6):901-906. doi: 10.1002/ppul.24321. Epub 2019 Mar 21.

PMID:
30897292
4.

Take it personally: how personal we reach when we are so different from each other?

Kerem E, Oren YS, Kerem B.

J Cyst Fibros. 2019 Jan;18(1):6-7. doi: 10.1016/j.jcf.2018.12.009. No abstract available.

PMID:
30665545
5.

Early onset children's interstitial lung diseases: Discrete entities or manifestations of pulmonary dysmaturity?

Bush A, Griese M, Seidl E, Kerem E, Reu S, Nicholson AG.

Paediatr Respir Rev. 2019 Apr;30:65-71. doi: 10.1016/j.prrv.2018.09.004. Epub 2018 Oct 9. Review.

PMID:
30552058
6.

Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age.

Shteinberg M, Lulu AB, Downey DG, Blumenfeld Z, Rousset-Jablonski C, Perceval M, Colombo A, Stein N, Livnat G, Gur M, Bentur L, Mussaffi H, Blau H, Sarouk I, Dagan A, Kerem E, Aviram M, Picard E, Aliberti S, Álvarez A, Miranda JP, Polverino E, Durieu I, Stuart Elborn J, Cohen-Cymberknoh M.

J Cyst Fibros. 2019 Jul;18(4):525-529. doi: 10.1016/j.jcf.2018.10.009. Epub 2018 Oct 23.

PMID:
30366850
7.

Evaluation of Soluble CD48 Levels in Patients with Allergic and Nonallergic Asthma in Relation to Markers of Type 2 and Non-Type 2 Immunity: An Observational Study.

Breuer O, Gangwar RS, Seaf M, Barhoum A, Kerem E, Levi-Schaffer F.

J Immunol Res. 2018 Sep 16;2018:4236263. doi: 10.1155/2018/4236263. eCollection 2018.

8.

Increasing Vitamin D Serum Levels Is Associated With Reduced Pulmonary Exacerbations in Patients With Cystic Fibrosis.

Abu-Fraiha Y, Elyashar-Earon H, Shoseyov D, Cohen-Cymberknoh M, Armoni S, Kerem E, Wilschanski M.

J Pediatr Gastroenterol Nutr. 2019 Jan;68(1):110-115. doi: 10.1097/MPG.0000000000002126.

PMID:
30095576
9.

Herpes Simplex Virus Pneumonia in an Immunocompetent Child on Corticosteroids for Acute Wheezing.

Pines N, Tsabari R, Kerem E, Reiter J.

Pediatr Emerg Care. 2018 May 23. doi: 10.1097/PEC.0000000000001519. [Epub ahead of print]

PMID:
29794958
10.

Respiratory manifestations in LPS-responsive beige-like anchor (LRBA) protein-deficient patients.

Shamriz O, Shadur B, NaserEddin A, Zaidman I, Simanovsky N, Elpeleg O, Kerem E, Reiter J, Stepensky P.

Eur J Pediatr. 2018 Aug;177(8):1163-1172. doi: 10.1007/s00431-018-3171-5. Epub 2018 May 18.

PMID:
29777306
11.

A quality improvement intervention to reduce emergency department radiography for bronchiolitis.

Reiter J, Breuer A, Breuer O, Hashavya S, Rekhtman D, Kerem E, Cohen-Cymberknoh M.

Respir Med. 2018 Apr;137:1-5. doi: 10.1016/j.rmed.2018.02.014. Epub 2018 Feb 19.

PMID:
29605191
12.

Attention deficit hyperactivity disorder symptoms in patients with cystic fibrosis.

Cohen-Cymberknoh M, Tanny T, Breuer O, Blau H, Mussaffi H, Kadosh D, Gartner S, Salinas A, Bentur L, Nir V, Gur M, Reiter J, Shoseyov D, Kerem E, Berger I.

J Cyst Fibros. 2018 Mar;17(2):281-285. doi: 10.1016/j.jcf.2017.11.020. Epub 2017 Dec 19.

PMID:
29269187
13.

A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness.

Guen VJ, Edvardson S, Fraenkel ND, Fattal-Valevski A, Jalas C, Anteby I, Shaag A, Dor T, Gillis D, Kerem E, Lees JA, Colas P, Elpeleg O.

Am J Med Genet A. 2018 Jan;176(1):92-98. doi: 10.1002/ajmg.a.38506. Epub 2017 Nov 12.

14.

Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.

Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC.

N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3.

15.

Clinical impact of Pseudomonas aeruginosa colonization in patients with Primary Ciliary Dyskinesia.

Cohen-Cymberknoh M, Weigert N, Gileles-Hillel A, Breuer O, Simanovsky N, Boon M, De Boeck K, Barbato A, Snijders D, Collura M, Pradal U, Blau H, Mussaffi H, Price M, Bentur L, Gur M, Aviram M, Picard E, Shteinberg M, Livnat G, Rivlin J, Hiller N, Shoseyov D, Amirav I, Kerem E.

Respir Med. 2017 Oct;131:241-246. doi: 10.1016/j.rmed.2017.08.028. Epub 2017 Sep 1.

PMID:
28947038
16.

Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.

Dagan A, Cohen-Cymberknoh M, Shteinberg M, Levine H, Vilozni D, Bezalel Y, Bar Aluma BE, Sarouk I, Ashkenazi M, Lavie M, Tsabari R, Blau H, Kerem E, Bentur L, Efrati O, Livnat G.

Respir Med. 2017 Oct;131:225-228. doi: 10.1016/j.rmed.2017.08.026. Epub 2017 Sep 1.

PMID:
28947035
17.

Predictors of Prolonged Hospitalizations in Pediatric Complicated Pneumonia.

Breuer O, Picard E, Benabu N, Erlichman I, Reiter J, Tsabari R, Shoseyov D, Kerem E, Cohen-Cymberknoh M.

Chest. 2018 Jan;153(1):172-180. doi: 10.1016/j.chest.2017.09.021. Epub 2017 Sep 21.

PMID:
28943281
18.

Congenital myopathy due to myosin heavy chain 2 mutation presenting as chronic aspiration pneumonia in infancy.

Tsabari R, Daum H, Kerem E, Fellig Y, Dor T.

Neuromuscul Disord. 2017 Oct;27(10):947-950. doi: 10.1016/j.nmd.2017.06.015. Epub 2017 Jun 27.

PMID:
28729039
19.

Cystic fibrosis: Priorities and progress for future therapies.

Kerem E.

Paediatr Respir Rev. 2017 Sep;24:14-16. doi: 10.1016/j.prrv.2017.06.004. Epub 2017 Jun 12. Review.

PMID:
28697970
20.

Nationwide genetic analysis for molecularly unresolved cystic fibrosis patients in a multiethnic society: implications for preconception carrier screening.

Behar DM, Inbar O, Shteinberg M, Gur M, Mussaffi H, Shoseyov D, Ashkenazi M, Alkrinawi S, Bormans C, Hakim F, Mei-Zahav M, Cohen-Cymberknoh M, Dagan A, Prais D, Sarouk I, Stafler P, Bar Aluma BE, Akler G, Picard E, Aviram M, Efrati O, Livnat G, Rivlin J, Bentur L, Blau H, Kerem E, Singer A.

Mol Genet Genomic Med. 2017 Feb 19;5(3):223-236. doi: 10.1002/mgg3.278. eCollection 2017 May.

21.

Autosomal dominant gain of function STAT1 mutation and severe bronchiectasis.

Breuer O, Daum H, Cohen-Cymberknoh M, Unger S, Shoseyov D, Stepensky P, Keller B, Warnatz K, Kerem E.

Respir Med. 2017 May;126:39-45. doi: 10.1016/j.rmed.2017.03.018. Epub 2017 Mar 22.

22.

Community paediatrics in Israel: the 'Goshen' model for change.

Porter B, Gadassi H, Grossman Z, Kerem E, Katz M, Oberklaid F.

Arch Dis Child. 2017 Sep;102(9):795-797. doi: 10.1136/archdischild-2016-312468. Epub 2017 Mar 9. No abstract available.

PMID:
28280095
23.

Collecting clinical data in primary ciliary dyskinesia- challenges and opportunities.

Amirav I, Roduta Roberts M, Mussaffi H, Mandelberg A, Roth Y, Abitbul R, Luder A, Blau H, Alkrinawi S, Aviram M, Ben-Ami M, Rotschild M, Bentur L, Shoseyov D, Cohen-Cymberknoh M, Kerem E, Avital A, Springer C, Hevroni A, Dabbah H, Elizur A, Picard E, Goldberg S, Rivlin J, Livnat G, Lavie M, Alias N, Soferman R, Olbrich H, Raidt J, Wallmeier J, Werner C, Loges NT, Omran H.

Version 2. F1000Res. 2016 Aug 18 [revised 2016 Jan 1];5:2031. eCollection 2016.

24.

Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function.

Wilschanski M, Yaakov Y, Omari I, Zaman M, Martin CR, Cohen-Cymberknoh M, Shoseyov D, Kerem E, Dasilva D, Sheth S, Uluer A, OʼSullivan BP, Freedman S.

J Pediatr Gastroenterol Nutr. 2016 Nov;63(5):e92-e97.

PMID:
27496797
25.

Equitable CF care as a basic human right.

De Boeck K, Kerem E.

J Cyst Fibros. 2016 Nov;15(6):703-704. doi: 10.1016/j.jcf.2016.09.006. Epub 2016 Oct 15. No abstract available.

26.

Primary ciliary dyskinesia in Israel: Prevalence, clinical features, current diagnosis and management practices.

Abitbul R, Amirav I, Blau H, Alkrinawi S, Aviram M, Shoseyov D, Bentur L, Avital A, Springer C, Lavie M, Prais D, Dabbah H, Elias N, Elizur A, Goldberg S, Hevroni A, Kerem E, Luder A, Roth Y, Cohen-Cymberknoh M, Ben Ami M, Mandelberg A, Livnat G, Picard E, Rivlin J, Rotschild M, Soferman R, Loges NT, Olbrich H, Werner C, Wolter A, Herting M, Wallmeier J, Raidt J, Omran H, Mussaffi H.

Respir Med. 2016 Oct;119:41-47. doi: 10.1016/j.rmed.2016.08.015. Epub 2016 Aug 23.

27.

[EXERCISE CAPACITY AND AEROBIC PHYSICAL FITNESS ASSESSMENT AMONG ADOLESCENTS AND ADULTS WITH CYSTIC FIBROSIS BY A QUESTIONNAIRE AND EXERCISE TESTS].

Eisenstadt I, Nice S, Constantini N, Kerem E, Calderon-Margalit R.

Harefuah. 2016 Jun;155(6):352-6, 387, 386. Hebrew.

PMID:
27544987
28.

Complicated community acquired pneumonia in childhood: Different types, clinical course, and outcome.

Erlichman I, Breuer O, Shoseyov D, Cohen-Cymberknoh M, Koplewitz B, Averbuch D, Erlichman M, Picard E, Kerem E.

Pediatr Pulmonol. 2017 Feb;52(2):247-254. doi: 10.1002/ppul.23523. Epub 2016 Jul 8.

PMID:
27392317
29.

Variable phenotypic presentation of a novel FOXF1 missense mutation in a single family.

Reiter J, Szafranski P, Breuer O, Perles Z, Dagan T, Stankiewicz P, Kerem E.

Pediatr Pulmonol. 2016 Sep;51(9):921-7. doi: 10.1002/ppul.23425. Epub 2016 May 4.

PMID:
27145217
30.

Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis.

Cohen-Cymberknoh M, Gilead N, Gartner S, Rovira S, Blau H, Mussaffi H, Rivlin J, Gur M, Shteinberg M, Bentur L, Livnat G, Aviram M, Picard E, Tenenbaum A, Armoni S, Breuer O, Shoseyov D, Kerem E.

J Cyst Fibros. 2016 Nov;15(6):776-782. doi: 10.1016/j.jcf.2016.04.006. Epub 2016 May 1.

31.

Pathogenetics of alveolar capillary dysplasia with misalignment of pulmonary veins.

Szafranski P, Gambin T, Dharmadhikari AV, Akdemir KC, Jhangiani SN, Schuette J, Godiwala N, Yatsenko SA, Sebastian J, Madan-Khetarpal S, Surti U, Abellar RG, Bateman DA, Wilson AL, Markham MH, Slamon J, Santos-Simarro F, Palomares M, Nevado J, Lapunzina P, Chung BH, Wong WL, Chu YWY, Mok GTK, Kerem E, Reiter J, Ambalavanan N, Anderson SA, Kelly DR, Shieh J, Rosenthal TC, Scheible K, Steiner L, Iqbal MA, McKinnon ML, Hamilton SJ, Schlade-Bartusiak K, English D, Hendson G, Roeder ER, DeNapoli TS, Littlejohn RO, Wolff DJ, Wagner CL, Yeung A, Francis D, Fiorino EK, Edelman M, Fox J, Hayes DA, Janssens S, De Baere E, Menten B, Loccufier A, Vanwalleghem L, Moerman P, Sznajer Y, Lay AS, Kussmann JL, Chawla J, Payton DJ, Phillips GE, Brosens E, Tibboel D, de Klein A, Maystadt I, Fisher R, Sebire N, Male A, Chopra M, Pinner J, Malcolm G, Peters G, Arbuckle S, Lees M, Mead Z, Quarrell O, Sayers R, Owens M, Shaw-Smith C, Lioy J, McKay E, de Leeuw N, Feenstra I, Spruijt L, Elmslie F, Thiruchelvam T, Bacino CA, Langston C, Lupski JR, Sen P, Popek E, Stankiewicz P.

Hum Genet. 2016 May;135(5):569-586. doi: 10.1007/s00439-016-1655-9. Epub 2016 Apr 12.

32.

Treatment of cystic fibrosis in low-income countries.

Cohen-Cymberknoh M, Shoseyov D, Breuer O, Shamali M, Wilschanski M, Kerem E.

Lancet Respir Med. 2016 Feb;4(2):91-2. doi: 10.1016/S2213-2600(15)00507-X. No abstract available.

PMID:
26868623
33.

Hepatopulmonary Syndrome in Patients With Cystic Fibrosis and Liver Disease.

Breuer O, Shteyer E, Wilschanski M, Perles Z, Cohen-Cymberknoh M, Kerem E, Shoseyov D.

Chest. 2016 Feb;149(2):e35-e38. doi: 10.1016/j.chest.2015.10.040.

34.

Disparities in Cystic Fibrosis Care and Outcome: Socioeconomic Status and Beyond.

Kerem E, Cohen-Cymberknoh M.

Chest. 2016 Feb;149(2):298-300. doi: 10.1016/j.chest.2015.08.021. No abstract available.

PMID:
26867826
35.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS.

J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.

36.

Reversible airway obstruction in cystic fibrosis: Common, but not associated with characteristics of asthma.

Levine H, Cohen-Cymberknoh M, Klein N, Hoshen M, Mussaffi H, Stafler P, Breuer O, Kerem E, Blau H.

J Cyst Fibros. 2016 Sep;15(5):652-9. doi: 10.1016/j.jcf.2016.01.003. Epub 2016 Jan 28.

37.

Adherence pattern to study drugs in clinical trials by patients with cystic fibrosis.

Pugatsch T, Shoseyov D, Cohen-Cymberknoh M, Hayut B, Armoni S, Griese M, Kerem E.

Pediatr Pulmonol. 2016 Feb;51(2):143-6. doi: 10.1002/ppul.23344. Epub 2015 Nov 19.

PMID:
26583331
38.

CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation.

Tsabari R, Elyashar HI, Cymberknowh MC, Breuer O, Armoni S, Livnat G, Kerem E, Zangen DH.

J Cyst Fibros. 2016 May;15(3):e25-7. doi: 10.1016/j.jcf.2015.10.012. Epub 2015 Nov 4.

39.

Persistent Tachypnea of Infancy. Usual and Aberrant.

Rauch D, Wetzke M, Reu S, Wesselak W, Schams A, Hengst M, Kammer B, Ley-Zaporozhan J, Kappler M, Proesmans M, Lange J, Escribano A, Kerem E, Ahrens F, Brasch F, Schwerk N, Griese M; PTI (Persistent Tachypnea of Infancy) Study Group of the Kids Lung Register.

Am J Respir Crit Care Med. 2016 Feb 15;193(4):438-47. doi: 10.1164/rccm.201508-1655OC.

40.

The impact of a national population carrier screening program on cystic fibrosis birth rate and age at diagnosis: Implications for newborn screening.

Stafler P, Mei-Zahav M, Wilschanski M, Mussaffi H, Efrati O, Lavie M, Shoseyov D, Cohen-Cymberknoh M, Gur M, Bentur L, Livnat G, Aviram M, Alkrinawi S, Picard E, Prais D, Steuer G, Inbar O, Kerem E, Blau H.

J Cyst Fibros. 2016 Jul;15(4):460-6. doi: 10.1016/j.jcf.2015.08.007. Epub 2015 Sep 16.

41.

Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis.

Gileles-Hillel A, Shoseyov D, Polacheck I, Korem M, Kerem E, Cohen-Cymberknoh M.

Pediatr Pulmonol. 2015 Nov;50(11):1082-9. doi: 10.1002/ppul.23302. Epub 2015 Sep 18.

PMID:
26383963
42.

Implementation of a Policy Change: Replacement of Nebulizers by Spacers for the Treatment of Asthma in Children.

Breuer O, Shoseyov D, Kerem E, Brooks R.

Isr Med Assoc J. 2015 Jul;17(7):421-4.

43.

The Moderating Role of Genetics: The Effect of Length of Hospitalization on Children's Internalizing and Externalizing Behaviors.

Benish-Weisman M, Kerem E, Knafo-Noam A, Belsky J.

Front Psychiatry. 2015 Aug 17;6:109. doi: 10.3389/fpsyt.2015.00109. eCollection 2015.

44.

Immunofluorescence Analysis and Diagnosis of Primary Ciliary Dyskinesia with Radial Spoke Defects.

Frommer A, Hjeij R, Loges NT, Edelbusch C, Jahnke C, Raidt J, Werner C, Wallmeier J, Große-Onnebrink J, Olbrich H, Cindrić S, Jaspers M, Boon M, Memari Y, Durbin R, Kolb-Kokocinski A, Sauer S, Marthin JK, Nielsen KG, Amirav I, Elias N, Kerem E, Shoseyov D, Haeffner K, Omran H.

Am J Respir Cell Mol Biol. 2015 Oct;53(4):563-73. doi: 10.1165/rcmb.2014-0483OC.

45.

Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy.

Breuer O, Blich O, Cohen-Cymberknoh M, Averbuch D, Kharasch S, Shoseyov D, Kerem E.

Pediatr Pulmonol. 2015 May;50(5):495-502. doi: 10.1002/ppul.23159. Epub 2015 Feb 4.

PMID:
25652187
46.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA.

J Cyst Fibros. 2015 Jul;14(4):507-14. doi: 10.1016/j.jcf.2014.12.013. Epub 2015 Jan 13.

47.

Genetic and electrophysiological characteristics of recurrent acute pancreatitis.

Werlin S, Konikoff FM, Halpern Z, Barkay O, Yerushalmi B, Broide E, Santo E, Shamir R, Shaoul R, Shteyer E, Yaakov Y, Cohen M, Kerem E, Ruszniewski P, Masson E, Ferec C, Wilschanski M.

J Pediatr Gastroenterol Nutr. 2015 May;60(5):675-9. doi: 10.1097/MPG.0000000000000623.

PMID:
25383785
48.

Is infection with hypermutable Pseudomonas aeruginosa clinically significant?

Auerbach A, Kerem E, Assous MV, Picard E, Bar-Meir M.

J Cyst Fibros. 2015 May;14(3):347-52. doi: 10.1016/j.jcf.2014.09.011. Epub 2014 Oct 11.

49.

Continuous intravenous β-lactam antibiotics in cystic fibrosis patients with severe drug hypersensitivity.

Breuer O, Cohen-Cymberknoh M, Armoni S, Kerem E, Shoseyov D.

Ann Allergy Asthma Immunol. 2014 Aug;113(2):229-30. doi: 10.1016/j.anai.2014.05.014. Epub 2014 Jun 13. No abstract available.

PMID:
24934107
50.

European Cystic Fibrosis Society Standards of Care: a road map to improve CF outcome.

Kerem E, Webb AK.

J Cyst Fibros. 2014 Jul;13(4):357-8. doi: 10.1016/j.jcf.2014.05.003. Epub 2014 May 29. No abstract available.

Supplemental Content

Support Center